ViraCoat has developed a novel Virucidal, Antiviral & Antimicrobial coating (Neutrapodal™ Technology) which has been scientifically demonstrated to have profound antiviral properties against SARS-CoV-2 (including new variants), Influenza (PR8 strain), and Bacteria (E. coli).
Viracoat’s patented Coating has been incorporated into the ViraCoat COVID-19 eliminating Antiviral FFP2 Mask at a manufacturing level, to inactivate the virus and help reduce the spread of SARS-CoV-2, other viruses, and bacteria within 5 minutes of contact.
The mask is manufactured in the UK by ViraCoat in state-of-the-art Module D PPE manufacturing facilities.
How many organisations/clients currently utilise the service/solution across the UK?
ViraCoat works with a broad range of commercial, private and government-owned users throughout the UK.
Is there anything you would like to make delegates aware of ahead of the IPC & HFM Conference in Scotland?
A subsidiary of ViraCorp, ViraCoat has developed a novel Virucidal, Antiviral & Antimicrobial Coating which has been demonstrated to have profound antiviral properties against SARS-CoV-2 (including new strains), Influenza (PR8 strain), and Bacteria (E. coli).
What do you feel are the key points delegates need to digest when considering a partnership with your organisation?
ViraCoat Ltd is seeking to carefully select a distribution partner for the UK and Europe for its virucidal, antimicrobial FFP2 face mask and other ViraCoat products as they come online in the future. A strong existing network of corporate clients who purchase PPE in high volumes, with a focus on the highest possible quality, is the ideal partner for ViraCoat Ltd. ViraCoat masks are fast becoming known as a the new benchmark for infection prevention and enhanced protection PPE.
Do you want to add any other key points?
Refer to www.viracoat.gobal for more information